Product Description
Diazoxide is used to manage symptoms of hypoglycemia (low blood sugar) that is caused by pancreas cancer, surgery, or other conditions. Diazoxide works by preventing release of insulin from the pancreas (Sourced from: https://www.mayoclinic.org/drugs-supplements/diazoxide-oral-route/proper-use/drg-20063406?p=1)
Mechanisms of Action: Potassium Channel Activator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Bangladesh | Brazil | Canada | Chile | Colombia | France | Greece | India | Ireland | Italy | Japan | Korea | Lithuania | Malta | Mexico | New Zealand | Russia | Slovenia | Switzerland | Taiwan | Thailand | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|